N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.

Monoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of numerous different protein variants and modifications. N-glycosylation as one of the most complex post-translational modification influences the structural characteristics of the antibodies Fc part thereby potentially modulating effector function and pharmacokinetics. Several investigations on the relationship between N-glycosylation and pharmacokinetics have been published. However, this structure-function relationship is not fully understood. In this review potential alterations with focus on N-glycosylation of mAbs and Fc fusion proteins and the possible effects on the pharmacokinetics are reviewed and the current understandings of the underlying mechanisms are described.

• Publication year

  2016

• Venue

  European journal of pharmaceutics and biopharmaceutics

• Publication date

  2016-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejpb.2016.01.005PMID 26775146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Real‐time product attribute control to manufacture antibodies with defined N‐linked glycan levels

  2015cited by this paper
• N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical

  2015cited by this paper
• Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins

  2014cited by this paper
• Impact of Glycation on Antibody Clearance

  2014cited by this paper
• Nanoscale reversed-phase liquid chromatography–mass spectrometry of permethylated N-glycans

  2013cited by this paper
• The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris

  2013cited by this paper
• Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals

  2013cited by this paper
• GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

  2012cited by this paper
• Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans

  2012cited by this paper
• The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris

  2012cited by this paper
• Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis.

  2012cited by this paper
• Rates and impact of human antibody glycation in vivo.

  2012cited by this paper
• Disulfide bond structures of IgG molecules

  2012cited by this paper
• Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome.

  2012cited by this paper
• Increased serum clearance of oligomannose species present on a human IgG1 molecule

  2012cited by this paper
• Marketed therapeutic antibodies compendium

  2012cited by this paper
• New high-performance liquid chromatography assay for glycosyltransferases based on derivatization with anthranilic acid and fluorescence detection.

  2012cited by this paper
• Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping.

  2011cited by this paper
• Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals

  2011cited by this paper
• Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.

  2011cited by this paper
• N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies

  2011cited by this paper
• NMR Analysis Demonstrates Immunoglobulin G N-glycans are Accessible and Dynamic

  2011cited by this paper
• Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials.

  2011cited by this paper
• High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.

  2011cited by this paper
• Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.

  2011cited by this paper
• Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis.

  2011cited by this paper
• C‐terminal lysine processing of human immunoglobulin G2 heavy chain in vivo

  2011cited by this paper
• The impact of glycosylation on monoclonal antibody conformation and stability

  2011cited by this paper
• Isomerization in the CDR2 of a monoclonal antibody: Binding analysis and factors that influence the isomerization rate

  2010cited by this paper
• HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals

  2010cited by this paper
• Impact of Glycosylation on Effector Functions of Therapeutic IgG †

  2010cited by this paper
• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

  2010cited by this paper
• Naturally occurring glycan forms of human immunoglobulins G1 and G2.

  2010cited by this paper
• GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins

  2010cited by this paper
• Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding*

  2010cited by this paper
• Pharmacological significance of glycosylation in therapeutic proteins.

  2009cited by this paper
• High-throughput immunoglobulin G N-glycan characterization using rapid resolution reverse-phase chromatography tandem mass spectrometry.

  2009cited by this paper
• Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies.

  2009cited by this paper
• Glycosylation as a strategy to improve antibody-based therapeutics

  2009cited by this paper
• Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass*

  2008cited by this paper
• Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins.

  2008cited by this paper
• Heterogeneity of monoclonal antibodies.

  2008cited by this paper
• Capillary electrophoresis-electrospray ionization mass spectrometry for rapid and sensitive N-glycan analysis of glycoproteins as 9-fluorenylmethyl derivatives.

  2008cited by this paper
• The effect of Fc glycan forms on human IgG2 antibody clearance in humans.

  2008cited by this paper
• Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model

  2008cited by this paper
• Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype

  2008cited by this paper
• Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.

  2008cited by this paper
• Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

  2008cited by this paper
• Glutamine deamidation of a recombinant monoclonal antibody.

  2008cited by this paper
• Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms*

  2008cited by this paper
• Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice.

  2008cited by this paper
• The Mechanism of Human Nonhomologous DNA End Joining*

  2008cited by this paper
• Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content.

  2008cited by this paper
• On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies.

  2008cited by this paper
• Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.

  2007cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

  2007cited by this paper
• Antibody structure, instability, and formulation.

  2007cited by this paper
• Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.

  2007cited by this paper
• Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.

  2007cited by this paper
• Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry.

  2007cited by this paper
• Antibody structure

  2006cited by this paper
• Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

  2006cited by this paper
• Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization.

  2006cited by this paper
• Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

  2006cited by this paper
• Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

  2006cited by this paper
• In vivo deamidation characterization of monoclonal antibody by LC/MS/MS.

  2005cited by this paper
• The mannose receptor: linking homeostasis and immunity through sugar recognition.

  2005cited by this paper
• Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies.

  2005cited by this paper
• From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor.

  2004cited by this paper
• Antibody pharmacokinetics and pharmacodynamics.

  2004cited by this paper
• Normal-phase nanoscale liquid chromatography-mass spectrometry of underivatized oligosaccharides at low-femtomole sensitivity.

  2004cited by this paper
• Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity

  2004cited by this paper
• The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*

  2003cited by this paper
• Reversed-phase ion-pairing liquid chromatography/ion trap mass spectrometry for the analysis of negatively charged, derivatized glycans.

  2003cited by this paper
• Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.

  2003cited by this paper
• Capillary electrophoresis/electrospray ion trap mass spectrometry for the analysis of negatively charged derivatized and underivatized glycans.

  2002cited by this paper
• Recognition of immunoglobulins by Fcgamma receptors.

  2002cited by this paper
• Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis

  2002cited by this paper
• Recognition of immunoglobulins by Fcγ receptors

  2002cited by this paper
• Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding.

  2001cited by this paper
• Identification of multiple sources of charge heterogeneity in a recombinant antibody.

  2001cited by this paper
• Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding*

  2001cited by this paper
• The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

  2000cited by this paper
• Isoaspartate in peptides and proteins: formation, significance, and analysis.

  2000cited by this paper
• The Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain Variable Region Locus

  1998cited by this paper
• High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid.

  1998cited by this paper
• Differential clearance of glycoforms of IgG in normal and autoimmune‐prone mice

  1996cited by this paper
• The asialoglycoprotein receptor: relationships between structure, function, and expression.

  1995cited by this paper
• Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology.

  1994cited by this paper
• Carbohydrate-specific receptors of the liver.

  1982cited by this paper
• Continuous cultures of fused cells secreting antibody of predefined specificity

  1975cited by this paper
• The role of sialic acid in determining the survival of glycoproteins in the circulation.

  1971cited by this paper
• The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses.

  1968cited by this paper
• Production

  1929cited by this paper

• Multimodal Chromatography in the Downstream Processing of mAb-Based Products: Mechanisms, Strategies, and Applications.

  2026cites this paper
• Glycosylation control strategies for recombinant therapeutic proteins in CHO cells.

  2026cites this paper
• Multiple analysis based on dual-mode anion-exchange chromatography strategy reveals significant impact of charge heterogeneity on structure and function of dulaglutide.

  2025cites this paper
• Radiolabeled porphyrin–antibody conjugates — A review of early work

  2025cites this paper
• Modulation of N-Glycosylation in Bispecific Antibody Biosimilars through Combined Modulators.

  2025cites this paper
• Characterization of deglycosylated anti-cocaine mAb by differential scanning fluorimetry and fluorescence labeling

  2025cites this paper
• Purification of a Fc-Fusion Protein with [Bathophenathroline:metal] Complexes

  2025cites this paper
• Microfluidic mimicry of the Golgi-linked N-glycosylation machinery.

  2025cites this paper
• An integrated protocol based on workflows of imaged capillary isoelectric focusing (icIEF) for in-depth protein heterogenous characterization: high-efficient fractionation and online mass spectrometry detection

  2025cites this paper
• The importance of IgG N-glycosylation in Health, Disease, and Neonatal hemochromatosis

  2025cites this paper
• Characterization and quantification of therapeutic monoclonal antibodies, anti-drug antibodies and their interactions for clinical applications

  2025cites this paper
• Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges

  2025cites this paper
• Dissecting antibody-dependent enhancement modulation by Fc-modified cross-neutralizing human monoclonal antibody

  2025cites this paper
• De novo sequencing of complex glycans by ion mobility-mass spectrometry using a self-expanding reference database

  2025cites this paper
• Refining proteoform characterization in biopharmaceuticals: A paradigm for the impact of pI markers and carrier ampholytes in imaged capillary isoelectric focusing tandem mass spectrometry.

  2025cites this paper
• New insights into phytochemicals via protein glycosylation focused on aging and diabetes.

  2025cites this paper
• Duckweeds for Plant Molecular Farming: Advances, Challenges, and Future Directions

  2025cites this paper
• N-glycosylation signature and its relevance in cardiovascular immunometabolism.

  2025cites this paper
• De novo sequencing of glycans by ion mobility-mass spectrometry using a self-expanding database

  2025cites this paper
• Altered Glycosylation of Subclass IgG1 Recombinant Human Immunoglobulin by Selecting Culture Conditions for Producers and Additives

  2025cites this paper
• Enzymatic Desialylation Enables Reliable Charge Variant Characterization of Highly Glycosylated and Sialylated Fc Fusion Proteins.

  2025cites this paper
• Pharmacokinetic considerations and strategies for antibody-based therapeutics

  2025cites this paper
• Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications

  2025cites this paper
• Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations

  2025cites this paper
• MS-Based Glycome Characterization of Biotherapeutics With N- and O-Glycosylation.

  2025cites this paper
• Recent developments of imaged capillary isoelectric focusing technology for in-depth biopharmaceutical characterization

  2025cites this paper
• Protein Post-Translational Modifications in CAR-T Cells: Novel Strategies to Amplify Antitumor Efficacy via Epigenetic and Metabolic Circuitry.

  2025cites this paper
• Enhancing the persistence of engineered biotherapeutics in the gut: Adhesion, glycan metabolism, and environmental resistance.

  2025cites this paper
• The impact of Fc glycosylation on IgG susceptibility to hinge region chemical reduction: implications for the development of immunoassays

  2025cites this paper
• Insights into O-GlcNAcylation and programmed cell death in cancer

  2025cites this paper
• Advancing protein heterogeneity analysis: nano-flow pressure mobilization for precise icIEF fractionation and online MS detection.

  2025cites this paper
• Spotlight on Glycan Pairing: The Generation and Impact of Monoclonal Antibody Asymmetrical Fc N‑Glycan Pairs on Fc Receptor Interaction.

  2025cites this paper
• Regulated bioanalysis of antibody-drug conjugates using LC-MS.

  2025cites this paper
• Novel L-Asparaginase from Paucilactobacillus vaccinostercus: Insights into Anti-Cancer Potential using Metagenomic, Molecular Docking and Molecular Dynamics Simulation

  2025cites this paper
• Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer Therapy.

  2025cites this paper
• Antibody Aggregation: A Problem Within the Biopharmaceutical Industry and Its Role in AL Amyloidosis Disease

  2024cites this paper
• Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation

  2024cites this paper
• In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry.

  2024cites this paper
• Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications.

  2024cites this paper
• The role of pharmaceutical laboratories in drug development and quality control

  2024cites this paper
• Improving Glycoproteomic Analysis Workflow by Systematic Evaluation of Glycopeptide Enrichment, Quantification, Mass Spectrometry Approach, and Data Analysis Strategies.

  2024cites this paper
• A chemoenzymatic method for simultaneous profiling N- and O-glycans on glycoproteins using one-pot format

  2024cites this paper
• A new paradigm for optimized experimental design in cIEF platforms aimed at an accurate robust and reliable mAbs charge-variant assessment

  2024cites this paper
• Simulation study of a new racetrack FAIMS analyzer to achieve both high-resolution and high-sensitivity.

  2024cites this paper
• Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing

  2024cites this paper
• Maduramycin, a novel glycosylation modulator for mammalian fed-batch and steady-state perfusion processes.

  2024cites this paper
• Characterization of Monoclonal Antibody N-Glycan Conformations by Novel Hydrophilic Interaction Liquid Chromatography (HILIC) with Trapped Ion Mobility Mass Spectrometry (TIMS) and Fluorescence Detection (FLD)

  2024cites this paper
• Hybrid Mass Spectrometry Applied across the Production of Antibody Biotherapeutics

  2024cites this paper
• Mass spectrometry-based structure-specific N-glycoproteomics and biomedical applications

  2024cites this paper
• Decoding Protein Glycosylation by an Integrative Mass Spectrometry-Based De Novo Sequencing Strategy

  2024cites this paper
• Escherichia coli and Pichia pastoris: microbial cell-factory platform for full-length IgG production

  2024cites this paper
• Experimentally Determined Diagnostic Ions for Identification of Peptide Glycotopes.

  2024cites this paper
• An integrated protocol based on workflows of imaged capillary isoelectric focusing (icIEF) for in-depth protein heterogenous characterization: high-efficient fractionation and online mass spectrometry detection

  2024cites this paper
• Comprehensive analysis and characterization of glycan pairing in therapeutic antibodies and Fc-containing biotherapeutics: Addressing current limitations and implications for N-glycan impact.

  2024cites this paper
• Comparative analysis of Herceptin N-Linked glycosylation by HILIC-FLD and LC-MS/MS methods.

  2024cites this paper
• Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture

  2024cites this paper
• Application of fucosylation inhibitors for production of afucosylated antibody

  2024cites this paper
• LC-MS/MS-Based Site-Specific N-Glycosylation Analysis of VEGFR-IgG Fusion Protein for Sialylation Assessment Across IEF Fractions

  2024cites this paper
• Mass spectrometry study on SARS-CoV-2 recombinant vaccine with comprehensive separation techniques to characterize complex heterogeneity.

  2024cites this paper
• Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

  2024cites this paper
• Affinity-Resolved Size Exclusion Chromatography Coupled to Mass Spectrometry: A Novel Tool to Study the Attribute-and-Function Relationship in Therapeutic Monoclonal Antibodies

  2024cites this paper
• Comparison of Four Rapid N-Glycan Analytical Methods and Great Application Potential in Cell Line Development

  2024cites this paper
• Glycan Complexity and Heterogeneity of Glycoproteins in Somatic Extracts and Secretome of the Infective Stage of the Helminth Fasciola hepatica

  2023cites this paper
• Systematic optimization, characterization of Mycophenolic acid loaded nanostructured lipid carrier embedded nanogel for improved permeation and in vivo anti psoriatic activity

  2023cites this paper
• Unveiling the multifaceted landscape of N-glycosylation in antibody variable domains: Insights and implications.

  2023cites this paper
• “Regulatory Sandboxes” Could Solve the Regulatory Problems Encountered in Europe and Arising from Innovation in Biological Medicinal Products

  2023cites this paper
• Trastuzumab Charge Variants: a Study on Physicochemical and Pharmacokinetic Properties

  2023cites this paper
• Imaged capillary isoelectric focusing tandem high-resolution mass spectrometry using nano electrospray ionization (ESI) for protein heterogeneity characterization.

  2023cites this paper
• Rapid Production of Cyclic Citrullinated Peptide Monoclonal Antibody in Nicotiana benthamiana for the Early Detection and Diagnosis of Rheumatoid Arthritis

  2023cites this paper
• Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates

  2023cites this paper
• Impact of Asialoglycoprotein Receptor and Mannose Receptor Deficiency on Murine Plasma N-glycome Profiles

  2023cites this paper
• What is the role of current mass spectrometry in pharmaceutical analysis?

  2023cites this paper
• Biosynthesis of protein-based drugs using eukaryotic microalgae

  2023cites this paper
• Site-Specific Antibody Conjugation Using Modified Bisected N-Glycans: Method Development and Potential toward Tunable Effector Function

  2023cites this paper
• Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates

  2023cites this paper
• In-Depth Characterization of mAb Charge Variants by On-Line Multidimensional Liquid Chromatography-Mass Spectrometry.

  2023cites this paper
• Glycoprotein In Vitro N-Glycan Processing Using Enzymes Expressed in E. coli

  2023cites this paper
• LC/MS Assessment of Glycoform Clearance of a Biotherapeutic mAb in Rabbit Ocular Tissues.

  2023cites this paper
• ZEIN NANOPARTICLES FOR DRUG DELIVERY: PREPARATION METHODS AND BIOLOGICAL APPLICATIONS.

  2023cites this paper
• Imaged capillary isoelectric focusing employing fluorocarbon and methylcellulose coated fused silica capillary for characterization of charge heterogeneity of protein biopharmaceuticals

  2023cites this paper
• Constant domain polymorphisms influence monoclonal antibody stability and dynamics

  2023cites this paper
• Identification, characterization, and engineering of glycosylation in thrombolyticsa.

  2023cites this paper
• Mass Spectrometry-Based Charge Heterogeneity Characterization of Therapeutic mAbs with Imaged Capillary Isoelectric Focusing and Ion-Exchange Chromatography as Separation Techniques.

  2023cites this paper
• Consistency of Product Quality for SB5, an Adalimumab Biosimilar

  2023cites this paper
• Equivalence assessment of biotherapeutics with N- and O-glycosylation sites by sequential intact glycoform mass spectrometry (IGMS).

  2023cites this paper
• "Lab of the Future"─Today: Fully Automated System for High-Throughput Mass Spectrometry Analysis of Biotherapeutics.

  2023cites this paper
• Integrating ultra-high performance liquid chromatography tandem mass spectrometry and imaged capillary isoelectric focusing for in-depth characterization of complex fusion proteins.

  2023cites this paper
• Understanding glycosylation: Regulation through the metabolic flux of precursor pathways.

  2023cites this paper
• Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review

  2023cites this paper
• Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms

  2022cites this paper
• Screening of group O platelet donors for high-titer ABO antibodies- limitations, feasibility, and future.

  2022cites this paper
• Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry

  2022cites this paper
• A rapid 2AB-UHPLC method based on magnetic beads extraction for N-glycan analysis of recombinant monoclonal antibody.

  2022cites this paper
• Analysis of Denosumab by a Validated CZE Method and Determination of Sialic Acids by the RP-HPLC Method.

  2022cites this paper
• In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.

  2022cites this paper
• Fractionation and online mass spectrometry based on imaged capillary isoelectric focusing (icIEF) for characterizing charge heterogeneity of therapeutic antibody.

  2022cites this paper
• Impact of N-Linked Glycosylation on Therapeutic Proteins

  2022cites this paper
• Controlled Release- Nanomedicine(CRNM) of aspirin using “Biomimetic Niosomal Nanoparticles (BNNs)”for Covid-19 and cardiovascular treatment: DOE based optimization

  2022cites this paper
• Mechanism of high-mannose N-glycan breakdown and metabolism by Bifidobacterium longum

  2022cites this paper
• Advanced assessment through intact glycopeptide analysis of Infliximab’s biologics and biosimilar

  2022cites this paper